Biopharmaceutical company Navidea Biopharmaceuticals Inc (NYSE American:NAVB) Friday disclosed an extension of the Lymphoseek patent, which has been assigned US patent 6,409,990, for an additional five years.
The US Food and Drug Administration (FDA) has reportedly released a letter indicating that the US Patent and Trademark Office (USPTO) is allowed to extend Lymphoseek's patent for an additional five years or until 12 May 2025.
In conjunction, the patent claims Lymphoseek (technetium (Tc 99m) tilmanocept) has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea.
Following the allowance of this patent extension, Cardinal Health and Navidea will extend their exclusive rights to manufacture and commercialise Lymphoseek until the end of the extended patent term in 2025.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach